Class / Patent application number | Description | Number of patent applications / Date published |
424246100 | Bacillus | 33 |
20080213316 | Destruction of spores through glycoconjugate enhanced phagocytosis - Methods for enhancing destruction and killing of bacterial spores via phagocytosis, where phagocytosis of bacterial spores is enhanced by using a glycoconjugate. In one embodiment, the method includes the steps of modifying a surface of a bacterial spore to increase adherence to a phagocyte; and ingesting the adherence-increased spore with the phagocyte, thereby destructing and killing the spore by blocking spore-induced phagocyte cell death, while increasing phagocyte activation level and production of antimicrobial and cytocidal agents such as NO and inflammatory cytokines. The adherence of spore to a phagocyte is increased after the surface thereof is coated with a glycoconjugate to form a glycoconjugate-coated spores. The glycoconjugate-coated spores also increase ingestion of the spores by phagocytes and facilitate phagosome-lysosome fusion, which in turn results in destruction and killing of bacterial spores via phagocytosis. The method enhances adherence, ingestion, destruction and killing of bacterial spores via phagocytes, which otherwise may be resistant to phagocytosis. | 09-04-2008 |
20080299153 | B. ANTHRACIS PREVENTION AND TREATMENT: MUTANT B. ANTHRACIS LACKING LUXS ACTIVITY AND FURANONE INHIBITION OF GROWTH, AI-2 QUORUM SENSING, AND TOXIN PRODUCTION - The present invention pertains to the discovery that | 12-04-2008 |
20090098164 | Spore associated display - The present invention concerns spore display methods. More specifically, the invention concerns display of heterologous molecules, such as peptides and polypeptides, on spores of bacilli, such as, for example, | 04-16-2009 |
20090110700 | ACELLULAR IMMUNOGENIC COMPOSITIONS AND ACELLULAR VACCINE COMPOSITIONS AGAINST BACILLUS ANTHRACIS - The invention concerns an acellular immunogenic or vaccine composition for producing antibodies against | 04-30-2009 |
20090175911 | Bacterial Production of Carotenoids - The present invention is based on a | 07-09-2009 |
20100015181 | Vaccine formulation - Spore coat-associated proteins from members of | 01-21-2010 |
20100098728 | Immunostimulating composition containing Lactic Acid bacteria - Producing an immunostimulating composition containing lactic acid bacteria having IL-12 production-inducing activity, by culturing lactic acid bacteria belonging to the genus Lactobacillus, immediately killing the bacteria at the point of time at which the pH of the culture medium substantially stops decreasing, and then adding the obtained killed cells to a food-or-drink product. | 04-22-2010 |
20100136058 | DNA vaccines against tumor growth and methods of use thereof - A DNA vaccine suitable for eliciting an immune response against cancer cells comprises a polynucleotide construct operably encoding an a Fra-1 protein, such as a polyubiquitinated human Fra-1 protein, and IL-18, such as human IL-18, in a pharmaceutically acceptable carrier. In a preferred embodiment, the polynucleotide construct is operably incorporated in an attenuated bacterial vector, such as an attenuated | 06-03-2010 |
20100143416 | Alpha-defensins as anthrax immunotherapeutis - The present invention relates to the use of an alpha-defensin in the manufacture of a medicament for the treatment, amelioration or prevention of a disease caused by | 06-10-2010 |
20100143417 | Compositions and methods for controlling diseases in animals - Disclosed herein are compositions for the treatment of a disease in an animal including yeast extract of | 06-10-2010 |
20100150965 | DNA PROMOTERS AND ANTHRAX VACCINES - The invention is related to intracellularly induced bacterial DNA promoters and vaccines against | 06-17-2010 |
20100178303 | STABLE ORGANIC-CARRIER-BASED MICROBIAL INOCULANTS AND METHOD FOR PRODUCING THE SAME - The present invention relates to methods for producing microbial preparations for crop production and microbial preparations produced through such methods. The formulations contain microbial inoculants like | 07-15-2010 |
20100183675 | Stable vaccine compositions and methods of use - A stable lyophilized protein formulation containing recombinant Protective Antigen (rPA) is described that can be reconstituted with a suitable diluent to generate a high potency protein concentration reconstituted formulation which is suitable for use as a vaccine against anthrax infection in mammals, especially human beings. These formulations were prepared by lyophilizing rPA in the presence of a reducing sugar, such as trehalose, and methods of such lyophilization are described. The resulting lyophilized mixture or composition is subsequently reconstituted to high immunogenicity without apparent loss of stability of the rPA protein. Methods of using said formulations in vaccination are also described. | 07-22-2010 |
20100226941 | METHOD OF PREVENTING INFECTIONS FROM BIOTERRORISM AGENTS WITH IMMUNOSTIMULATORY CPG OLIGONUCLEOTIDES - The present disclosure relates to a method of preventing or treating an infection caused by a bioterrorism agent, specifically to a method of increasing an immune response to a bioterrorism agent using an oligodeoxynucleotide including a CpG motif, and a method of enhancing the immunogenicity of a vaccine against a bioterrorism agent using an oligodeoxynucleotide including a CpG motif. | 09-09-2010 |
20100266639 | Expression system - An immunogenic reagent which produces an immune response which is protective against | 10-21-2010 |
20100272757 | BACILLUS ANTHRACIS PROTECTIVE ANTIGEN NUCLEIC ACID SEQUENCES - The invention relates to improved methods of producing and recovering B. anthracisprotective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, | 10-28-2010 |
20100291152 | CHEMICALLY MODIFIED PEPTIDES WITH IMPROVED IMMUNOGENICITY - The invention provides processes for improving the ability of a peptide to stimulate an immune response, comprising exposing the peptide to a chemical modifying agent. It further provides compositions comprising an antigenic peptide, wherein the peptide has been treated with a chemical modifying agent to improve its ability to stimulate an immune response. It also provides methods of stimulating an immune response in a mammal, comprising administering to the mammal an effective amount of a vaccine. | 11-18-2010 |
20110014235 | THERAPEUTIC AND VACCINE POLYELECTROLYTE NANOPARTICLE COMPOSITIONS - Polyelectrolyte nanoparticle compositions for biomedical applications are provided comprising at least two carrier domains comprising multivalent ionic domains and an agent exhibiting biological activity when contained within the nanoparticle or on the nanoparticle surface. The multivalent ionic domains may be contained in two separate molecules or in separate but linked domains of a single molecule. The nanoparticle optionally can further comprise an exposed targeting ligand and/or protective surface. The nanoparticle can be contacted to cells or administered directly to an animal for biomedical applications including therapeutics and immune response. The nanoparticle may alternatively be comprised of a carrier material capable of delivering various medically important antigens as vaccine. | 01-20-2011 |
20110014236 | NOVEL PROTEIN CAPABLE OF INHIBITING ANTHRAX TOXIN ACTIVITY - The invention particularly relates to inhibition of the cleavage of protective antigen (PA) of | 01-20-2011 |
20110171264 | Protein Formulation - An aqueous composition which comprises a protein or other biological molecule and also (i) optionally comprises one or more metal ions at a concentration of 0.01 to 20 mM; (ii) comprises excipients which are weak ligands; and (iii) is substantially free of excipients which are medium-strength ligands or strong ligands. | 07-14-2011 |
20110236425 | ANTHRAX VACCINE FORMULATION AND USES THEREOF - An anthrax vaccine with alhydrogel as the adjuvant is presented in a composition formulated by mixing rPA with colloidal alhydrogel (alum) adjuvant to produce the final product, comprising 200 μg/ml rPA bound to 0.26% alhydrogel in phosphate buffered saline (PBS), said formulation containing an optimal concentration of phosphate. Methods of using the vaccines to treat or prevent infections are also presented. | 09-29-2011 |
20110318386 | BACILLUS ISOLATES AND METHODS OF THEIR USE TO PROTECT AGAINST PLANT PATHOGENS - Methods of inducing systemic acquired resistance to infection in a plant by applying a composition comprising a | 12-29-2011 |
20120009219 | BACILLUS ANTHRACIS PROTECTIVE ANTIGEN SEQUENCES - The invention relates to improved methods of producing and recovering | 01-12-2012 |
20120021004 | MEDIUM AND METHOD OF DERIVING AND USING A MUTATED BACTERIA STRAIN - A new strain of | 01-26-2012 |
20120027799 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING INFLAMMATORY BOWEL DISEASE AND COLON CANCER - The invention provides compositions and methods for useful for the diagnosis of inflammatory bowel disease, ETBF-induced colitis, colonic hyperplasia and/or colon carcinogenesis in a subject in biological samples (e.g., stool, urine, blood, serum, tissue). The invention further provides compositions and methods for the treatment or prevention of colitis, colon cancer, or inflammatory bowel disease (e.g., Crohn's disease). | 02-02-2012 |
20120135038 | EXPRESSION OF PROTECTIVE ANTIGENS IN TRANSGENIC CHLOROPLASTS AND THE PRODUCTION OF IMPROVED VACCINES - Vaccines for conferring immunity in mammals to infective pathogens are provided, as well as vectors and methods for plastid transformation of plants to produce protective antigens and vaccines for oral delivery. The invention further provides transformed plastids having the ability to survive selection in both the light and the dark, at different developmental stages by using genes coding for two different enzymes capable of detoxifying the same selectable marker, driven by regulatory signals that are functional in proplastids as well as in mature chloroplasts. The invention utilizes antibiotic-free selectable markers to provide edible vaccines for conferring immunity to a mammal against | 05-31-2012 |
20130183345 | Treatment of Bladder Cancer Following Detection of Expression Levels of Certain Progression Markers - Disclosed is determining expression levels of protective or harmful markers for bladder cancer prognosis and treatment; particularly, determining the expression levels of protective markers (COL4A3BP, MBNL2, FABP4, NEK1 and SKAP2) and harmful markers (COL4A1, UBE2C, BIRC5, COL18A1, KPNA2, MSN, ACTA2, and CDC25B) and making treatment decisions in consideration of increased or decreased risk of progression based on the marker expression levels. | 07-18-2013 |
20130189308 | EXPRESSION OF PROTECTIVE ANTIGENS IN TRANSGENIC CHLOROPLASTS AND THE PRODUCTION OF IMPROVED VACCINES - Vaccines for conferring immunity in mammals to infective pathogens are provided, as well as vectors and methods for plastid transformation of plants to produce protective antigens and vaccines for oral delivery. The invention further provides transformed plastids having the ability to survive selection in both the light and the dark, at different developmental stages by using genes coding for two different enzymes capable of detoxifying the same selectable marker, driven by regulatory signals that are functional in proplastids as well as in mature chloroplasts. The invention utilizes antibiotic-free selectable markers to provide edible vaccines for conferring immunity to a mammal against | 07-25-2013 |
20130216577 | Methods And Compositions For The Dietary Management Of Autoimmune Disorders - The present invention describes the use of lactic acid bacteria, particularly lactic acid producing members of the genus | 08-22-2013 |
20140050764 | Inactivated Bacterial Cell Formulation - The invention relates to the use of lactic acid-producing bacteria to boost the immune system. | 02-20-2014 |
20140170188 | BACILLUS ANTHRACIS HtrA-DEFECTIVE-DERIVED VACCINES - The invention provides an isolated | 06-19-2014 |
20150079133 | METHOD OF VACCINE DELIVERY VIA MICRONEEDLE ARRAYS - A microprojection array is provided, comprising an approximately planar base and a plurality of microprojections, wherein the array comprises a vaccine and a polymeric material. The array may have multiple layers. The vaccine may be placed in only one layer. In another embodiment of the invention, a method of preventing a disease is provided, comprising insertion into the skin of a patient an array of microprojections comprising a layer which comprises a vaccine for that disease and a polymer. | 03-19-2015 |
20160074495 | Inactivated Bacterial Cell Formulation - The invention relates to the use of lactic acid-producing bacteria to boost the immune system. | 03-17-2016 |